More Than Just Risk: Genetic Testing Is Shaping Breast Cancer Treatment

https://investor.myriad.com/news-releases/news-release-detail/20351/

Myriad, AstraZeneca and Merck Expand Companion Diagnostic ...

“However, there is a significant unmet medical need in men with metastatic castration-resistant prostate cancer and BRCA1/2 mutations, which is an area ...

https://investor.myriad.com/news-releases/news-release-detail/11691/

Myriad and AbbVie Sign Expanded Agreement for Tumor ...

Nov 3, 2014 ... ... BRCA1 and BRCA2 genes. Tumor BRACAnalysis CDx has undergone significant analytic validation and has been shown to identify up to 50 percent ...

https://investor.myriad.com/news-releases/news-release-detail/10621/

Myriad Genetics Discovers COB1 Gene for Early-Onset Obesity

Sep 29, 2005 ... s geneticists to advance traditional positional cloning, the technique used in the 1990s to discover genes such as BRCA1 and BRCA2 for breast ...

https://investor.myriad.com/news-releases/news-release-detail/10886/

BRCA Testing Granted Preventive Care Designation Under the ...

Mar 6, 2013 ... Screening for deleterious mutations in the BRCA1 and BRCA2 genes was incorporated in the guidelines with a rating of "B" but due to some ...

https://investor.myriad.com/news-releases/news-release-detail/11101/

Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic ...

Jul 26, 2012 ... BRACAnalysis is a molecular diagnostic test developed by Myriad Genetics which analyzes the BRCA1 and BRCA2 genes to assess a woman's risk ...

https://investor.myriad.com/news-releases/news-release-detail/10586/

Supreme Court Upholds Myriad's cDNA Patent Claims

Jun 13, 2013 ... ... [BRCA1 and BRCA2] sequences, Myriad was in an excellent position to claim applications to that knowledge." "We believe the Court ...

https://investor.myriad.com/news-releases/news-release-detail/20141/

Peter D. Meldrum (1947-2018) - Investor relations - Myriad Genetics

Under his leadership, the company made numerous important strategic and scientific achievements including the discovery of the BRCA1/2 genes; the launch of ...

https://myriad.com/.../expanding-access-to-parp-inhibitors-in-prostate-canc...

Expanding access to PARP inhibitors in prostate cancer treatment

Mar 14, 2023 ... The patient populations shared mutations in BRCA1, BRCA2, ATM and/or other HRR genes. The subjects receiving Olaparib also trended toward an ...

https://investor.myriad.com/news-releases/news-release-detail/12251/

Myriad Genetics Will Present Results from Six Breast Cancer ...

Nov 28, 2016 ... ... BRCA1/2 breast cancer (CRUK/07/012). Presenter: Andrew Tutt. Date: Friday, Dec. 9, 2016: 3:15 p.m. CT. Location: S6-01; General Session 6 ...

https://myriad.com/.../more-than-just-risk-genetic-testing-is-shaping-breast-...

More Than Just Risk: Genetic Testing Is Shaping Breast Cancer ...

Nov 13, 2025 ... Recent guidelines now recommend offering germline BRCA1/2 testing to all breast cancer patients aged 65 or younger as well as most patients over ...